These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1373205)

  • 1. Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.
    Dedieu JF; Ronco J; van der Werf S; Hogle JM; Henin Y; Girard M
    J Virol; 1992 May; 66(5):3161-7. PubMed ID: 1373205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The construction and characterization of poliovirus antigen chimeras presenting defined regions of the human T lymphocyte marker CD4.
    Rose C; Andrews W; Ferguson M; McKeating J; Almond J; Evans D
    J Gen Virol; 1994 May; 75 ( Pt 5)():969-77. PubMed ID: 8176383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.
    Vella C; Ferguson M; Dunn G; Meloen R; Langedijk H; Evans D; Minor PD
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2603-7. PubMed ID: 7506299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and genetic analysis of dicistronic polioviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120.
    Lu HH; Alexander L; Wimmer E
    J Virol; 1995 Aug; 69(8):4797-806. PubMed ID: 7541843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses.
    Arnold GF; Resnick DA; Li Y; Zhang A; Smith AD; Geisler SC; Jacobo-Molina A; Lee W; Webster RG; Arnold E
    Virology; 1994 Feb; 198(2):703-8. PubMed ID: 7507283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.
    Evans DJ; McKeating J; Meredith JM; Burke KL; Katrak K; John A; Ferguson M; Minor PD; Weiss RA; Almond JW
    Nature; 1989 Jun; 339(6223):385-8, 340. PubMed ID: 2542797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling of poliovirus. HIV-1 antigen chimaeras.
    Crabbe MJ; Evans DJ; Almond JW
    FEBS Lett; 1990 Oct; 271(1-2):194-8. PubMed ID: 1699798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.
    Resnick DA; Smith AD; Gesiler SC; Zhang A; Arnold E; Arnold GF
    J Virol; 1995 Apr; 69(4):2406-11. PubMed ID: 7884887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    Nara PL; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Gallo RC; Fischinger PJ; Goudsmit J
    J Virol; 1990 Aug; 64(8):3779-91. PubMed ID: 2370681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
    Yoshiyama H; Mo H; Moore JP; Ho DD
    J Virol; 1994 Feb; 68(2):974-8. PubMed ID: 7507188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Kliks SC; Shioda T; Haigwood NL; Levy JA
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11518-22. PubMed ID: 7505441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.